Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.53 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | LSS | P48449 | 2/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | PROKR1 | Q8TCW9 | 3/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17896360 | 0.82 | MAP4K4 (0.50) | MAP4K4DRD2HTR1ADRD4DRD3 | |
| SCHEMBL17888358 | 0.82 | HTR1A (0.52) | MAP4K4DRD2HTR1ADRD4LSS | |
| SCHEMBL23114442 | 0.81 | MAP4K4 (0.50) | MAP4K4DRD2HTR1ADRD4DRD3 | |
| SCHEMBL12090447 | 0.81 | MAP4K4 (0.50) | MAP4K4DRD2HTR1ADRD4DRD3 | |
| SCHEMBL17896784 | 0.80 | MAP4K4 (0.52) | MAP4K4DRD2DRD3LSSKCNH2 | |
| SCHEMBL29814708 | 0.79 | DRD2 (0.45) | MAP4K4DRD2HTR1ADRD4DRD3 | |
| SCHEMBL23089594 | 0.79 | DRD2 (0.45) | MAP4K4DRD2HTR1ADRD4DRD3 | |
| SCHEMBL19016219 | 0.78 | MAP4K4 (0.47) | MAP4K4DRD2HTR1ADRD4DRD3 | |
| SCHEMBL17896785 | 0.78 | MAP4K4 (0.56) | MAP4K4DRD2DRD3LSSPARP1 | |
| SCHEMBL23114439 | 0.77 | KCNH2 (0.46) | DRD2DRD3LSSKCNH2PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2855459-B1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2020-04-29 | — | — | EP | disclosed |
| US-20170173026-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | GENENTECH, INC. (US) | 2017-06-22 | — | — | US | disclosed |
| US-9592235-B2 | Aminoquinazoline and pyridopyrimidine derivatives | GENENTECH, INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-20160296525-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | GENENTECH, INC. (US) | 2016-10-13 | — | — | US | disclosed |
| US-9382241-B2 | Aminoquinazoline and pyridopyrimidine derivatives | GENENTECH, INC. (US) | 2016-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160296525-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | DPYD, FANCD2, RECQL | MAP4K4 700/4885DRD2 1993/4885HTR1A 1654/4885 |
| US-20170173026-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | FLT4, FLT1, KDR | MAP4K4 662/4885DRD2 2514/4885HTR1A 1083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.